Page 6 - Element Type News Today

Frailty often coexists in kidney transplant candidates, care partners Source: Disclosures: Healio Nephrology was unable to determine relevant financial disclosures prior to publication. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Youve successfully added to your alerts. You will receive an email when new content is published. Back to Heal...

More than 200,000 people in the United States met the American College of Rheumatology criteria for systemic lupus erythematosus in 2018, according to data published in Arthritis & Rheumatology.The findings represent the first national estimate of SLE prevalence in the United States since the CDC established several registries to track the disease more than 10 years ago, read a press release

Diabetes complications differ according to ethnicity, disease-related subgroups ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Youve successfully added to your alerts. You will receive an email when new content is published. Back to Healio We were unable to process your request. Please try again later. If...

Dispositional, situational factors can mimic ICD-10 criteria for postconcussion syndrome ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Youve successfully added to your alerts. You will receive an email when new content is published. Back to Healio We were unable to process your request. Please try again ...

Depression rate lower with apremilast treatment for psoriasis, psoriatic arthritis Source: Vasilakis-Scaramozza C, et al. Rates of treated depression and anxiety among patients with psoriasis or psoriatic arthritis treated with apremilast, biologics, conventional DMARDs, and corticosteroids in a US commercial database. Presented at: Maui Derm for Dermatologists; Jan. 25-29, 2021; Maui, Hawaii (hybrid meeting). Disclosures: Vasilakis-Scaramozza reports she is an employee of the B...

Faricimab meets primary endpoints in phase 3 wet AMD studies Source/Disclosures Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Youve successfully added to your alerts. You will receive an email when new content is published. Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue p...

Infectious Disease News | On Feb. 1, 2016, almost 70 years after Zika was first discovered by chance in a forest in Uganda, WHO declared a global public health emergency over an increase in microcephaly and neurological complications linked to the virus.Five years later, despite advances in understanding the transmission, pathogenesis and clinical progression of the mosquito-borne disease, a lot is still unknown about

First-line pembrolizumab induced durable antitumor activity and promising OS among patients with advanced hepatocellular carcinoma, according to data from the phase 2 KEYNOTE-224 study presented at Gastrointestinal Cancers Symposium.Immunotherapy as monotherapy can offer “excellent benefit” for around 25% to 30% of patients in this setting, or it can be used in combinations to provide

Evolocumab, a PCSK9 inhibitor, in addition to statin therapy for stable atherosclerotic CVD may lower risk for future revascularization with PCI or CABG, according to findings published in the Journal of the American College of Cardiology. As Healio previously reported, in the main results of the FOURIER trial, LDL lowering to a median of 30 mg/dL with evolocumab (Repatha, Amgen) in ASCVD

The FDA granted accelerated approval to daratumumab plus hyaluronidase-fihj in combination with bortezomib, cyclophosphamide and dexamethasone for treatment of newly diagnosed light chain amyloidosis. Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) — a subcutaneous formulation of daratumumab (Darzalex, Janssen) — is approved for several indications for which IV